Compare BYFC & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BYFC | RLYB |
|---|---|---|
| Founded | 1946 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.4M | 89.2M |
| IPO Year | 2013 | 2021 |
| Metric | BYFC | RLYB |
|---|---|---|
| Price | $11.66 | $15.80 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.1K | ★ 22.0K |
| Earning Date | 07-28-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.07 | ★ 5.64 |
| Revenue | $184,000.00 | ★ $858,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $165.71 | ★ $2.79 |
| Revenue Growth | 18.71 | ★ 43.00 |
| 52 Week Low | $5.51 | $0.56 |
| 52 Week High | $12.35 | $32.54 |
| Indicator | BYFC | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | 63.80 | 37.68 |
| Support Level | $11.76 | $7.93 |
| Resistance Level | $12.27 | $16.89 |
| Average True Range (ATR) | 0.14 | 1.77 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 100.00 | 1.91 |
Broadway Financial Corp is active in the financial services domain. It is a savings and loan holding company in the United States. The Bank offers a variety of commercial real estate loan products, services, and depository accounts that support investments in affordable housing, small businesses, and nonprofit community facilities located within low-to-moderate income neighborhoods.
Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.